 |
 |
| |
|
Mr. Philip Yeo |
|
Mr.
Philip Yeo
is the Chairman of the Board of Directors for
A-Bio Pharma Pte Ltd. Mr Yeo is currently
the Special Advisor for Economic Development
(Prime Minister's Office), Senior Advisor for
Science and Technology (Ministry of Trade &
Industry) and Chairman of the Standards,
Productivity and Innovation Board (SPRING) in
Singapore
. He was formerly the Chairman of the
Agency for Science, Technology and Research
(A*STAR), the Economic Development Board (EDB)
and the National Computer Board (NCB). Prior
to these appointments, Mr Yeo served in the
Ministry of Defence where he held several
appointments including the appointment of
Permanent Secretary for Defence for logistics,
technology research & development and
defence industries. Mr. Yeo is the
recipient of many national and international
awards from industries, institutions and
governments, and was conferred an honorary
doctorate in Engineering from the
University
of
Toronto
and an honorary degree of Doctor of Medicine by
the Karolinska Institute. In addition, Mr.
Yeo is a board member in many listed companies.
|
|
Mr.
Clateo Castellini |
|
Mr.
Clateo Castellini holds a BA in Economics from
Bocconi University in Milano, Italy and
completed the Advanced Management Program at the
Harvard Business School. He started his career
in Lepetit , an Italian Pharmaceutical company,
which was later acquired by Dow Chemical. At
Lepetit and Dow he worked on various assignments
in Europe, South America and US. In 1978 Mr.
Castellini joined Becton, Dickinson &
Company and served in various postings around
the world and later was posted to the Corporate
Headquarter in New Jersey. In 1994 he became
Chairman, President and CEO of Becton, Dickinson
& Company and retired in 2002. He is
currently on the board of Quintiles
Transnational Corp. and A-Bio Pharma.
|
|
Ms.
Chu Swee Yeok |
|
Ms.
Chu Swee Yeok
is the Chief Executive Officer of Bio*One
Capital Pte Ltd, an investment management
company of the Singapore Economic Development
Board (SEDB). Ms Chu has more than 20
years of experience in investment and technology
promotion, strategic planning and business
development in biomedical sciences. She
led the establishment of Biomedical Sciences
Investment Fund, SEDB’s largest investment
fund of US$600 million in late 2000. Together
with three other funds, Bio*One Capital has more
than 60 portfolio companies globally. Ms
Chu holds several board directorship
responsibilities, including S*BIO Pte Ltd,
Merlion Pharmaceuticals Pte Ltd, CombinatoRx
Singapore, Lonza Biologics Tuas Pte Ltd,
Novartis Institute for Tropical Diseases and
Exploit Technologies Pte Ltd.
|
|
Mr.
John Nine |
|
Mr.
John Nine holds a BS degree in pharmacy and an
honorary science doctorate of pharmacy from
Purdue University.
He received an honorary science doctorate
of pharmacy from Arnold and Marie Schwartz
College of Pharmacy and Health Sciences, Long
Island University and an honorary doctorate of
Humane Letters from Florida A & M
University. Mr. Nine joined Schering-Plough in
1975 as vice president - pharmaceutical
production.
He later served as president - Schering
technical operations for Schering Laboratories.
He subsequently served as senior vice
president - Group C, and as president of
Schering-Plough K.K., Japan. He was a Corporate
Vice President
and President of Technical Operations. He
is currently on the Board of Yonkers Industries,
Cary, N. C., Aptuit and A-Bio and a Board
Advisor at The Chao Center for Pharmaceutical
Manufacturing. Mr. Nine served as the acting CEO
for A-Bio Pharma at its initiation phase.
|
|
Professor Daniel Wang |
|
Professor Daniel Wang holds
BS and PhD degrees in Chemical Engineering and
an MS degree in Biochemical Engineering. He is
an Institute Professor of Chemical Engineering
at the Massachusetts Institute of Technology and
a Temasek Professor at
the National University of Singapore.
For more than 20 years, Professor Wang
has held various positions and chairmanships in
a number of technology organizations in US,
Switzerland, Israel, China and Hong Kong. He is
noted for his research in the fields of
biotechnology and bioengineering and has served
on many editorial boards, having contributed
over 200 articles in journals relating to
biotechnology, bioengineering and chemical
engineering and authored or co-authored a number
of books. He is the
recipient of many awards and holds an Honorary
Doctorate in Engineering from Hong Kong
University of Science and Technology.
|
|
|
|
Professor
Miranda Gek Sim Yap |
|
Professor Miranda Gek Sim Yap
received her PhD in Chemical Engineering from
the University of Toronto, Canada. She is the
Executive Director of the Bioprocessing
Technology Institute (BTI) in Singapore and is
concurrently the Executive Director of A*STAR
Graduate Academy (A*GA). Her other
accomplishments include the formation of two
other organizations: the Centre for Natural
Product Research - now called Merlion
Pharmaceuticals Pte Ltd and the
Biopharmaceutical Manufacturing Technology
Centre - now known as A-Bio Pharma Pte Ltd.
Professor Yap is actively involved in research,
supervising PhD candidates in the area of Animal
Cell Technology and in developing manpower for
the biopharmaceutical industry in Singapore. In
February 2006, Professor Yap was named as a
Foreign Associate of the US National Academy of
Engineering for her achievements in education,
research and management in the field of
mammalian cell culture.
|
| |
|
 |
|
 |